Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023
May 11 2023 - 7:30AM
Matinas BioPharma (NYSE American: MTNB), a clinical-stage
biopharmaceutical company focused on delivering groundbreaking
therapies using its lipid nanocrystal (LNC) platform delivery
technology, announces that Jerome D. Jabbour, Chief Executive
Officer, will present a company overview at the JMP Securities Life
Sciences Conference on Monday, May 15, 2023 at 9:30 a.m. Eastern
time. The conference is being held at the New York Hilton Midtown.
A webcast of the presentation will be available
on the IR Calendar page of the Investors section of the Company’s
website following the event for 90 days.
About Matinas BioPharmaMatinas
BioPharma is a biopharmaceutical company focused on delivering
groundbreaking therapies using its lipid nanocrystal (LNC) platform
delivery technology to maximize global clinical impact and patient
access. The Company is developing its own internal portfolio of
products as well as partnering with leading pharmaceutical
companies to develop novel formulations that capitalize on the
unique characteristics of the LNC platform.
Preclinical and clinical data have demonstrated
that this novel technology can provide solutions to many of the
challenges in achieving safe and effective intracellular delivery
for both small molecules and larger, more complex molecules such as
siRNA, antisense oligonucleotides, and vaccines. The combination of
a unique mechanism of action and flexibility with formulation and
route of administration (including oral) positions Matinas’ LNC
technology potentially to become a preferred next-generation
intracellular drug delivery platform.
In addition, Matinas has recently developed a
non-LNC phosphatidylserine-based nanoparticle delivery technology
that takes advantage of the same unique biological properties of
phosphatidylserine that play a key role in more traditional LNCs,
but with its own unique structural characteristics that allow the
in vitro and in vivo delivery of larger oligonucleotides like mRNA,
with several distinct potential advantages over lipid nanoparticle
alternatives. For more information, please visit
www.matinasbiopharma.com.
Forward-looking StatementsThis
release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including
those relating to our business activities, our strategy and plans,
our collaboration with National Resilience, Inc., the potential of
our LNC platform and PS-NP delivery technologies, and the future
development of its product candidates, the Company’s ability to
identify and pursue development, licensing and partnership
opportunities for its products or platform delivery technologies on
favorable terms, if at all, and the ability to obtain required
regulatory approval and other statements that are predictive in
nature, that depend upon or refer to future events or conditions.
All statements other than statements of historical fact are
statements that could be forward-looking statements.
Forward-looking statements include words such as "expects,"
"anticipates," "intends," "plans," "could," "believes," "estimates"
and similar expressions. These statements involve known and unknown
risks, uncertainties and other factors which may cause actual
results to be materially different from any future results
expressed or implied by the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, our ability to obtain
additional capital to meet our liquidity needs on acceptable terms,
or at all, including the additional capital which will be necessary
to complete the clinical trials of our product candidates; our
ability to successfully complete research and further development
and commercialization of our product candidates; the uncertainties
inherent in clinical testing; the timing, cost and uncertainty of
obtaining regulatory approvals; our ability to protect the
Company’s intellectual property; the loss of any executive officers
or key personnel or consultants; competition; changes in the
regulatory landscape or the imposition of regulations that affect
the Company’s products; and the other factors listed under "Risk
Factors" in our filings with the SEC, including Forms 10-K, 10-Q
and 8-K. Investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this release. Except as may be required by law, the Company does
not undertake any obligation to release publicly any revisions to
such forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events. Matinas BioPharma’s product candidates are all in a
development stage and are not available for sale or use.
Investor Contact
LHA Investor RelationsJody Cain
Jcain@lhai.com310-691-7100
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Jul 2023 to Jul 2024